Maria Learoyd
About
Maria Learoyd is a scholar working on Oncology, Molecular Biology and Pharmacology.
According to data from OpenAlex, Maria Learoyd has authored 25 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Maria Learoyd's work include PARP inhibition in cancer therapy (12 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pneumonia and Respiratory Infections (4 papers). Maria Learoyd is often cited by papers focused on PARP inhibition in cancer therapy (12 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pneumonia and Respiratory Infections (4 papers). Maria Learoyd collaborates with scholars based in United Kingdom, United States and Netherlands. Maria Learoyd's co-authors include Timi Edeki, Shampa Das, J. Armstrong, James Li, Núria Sala, Fred Saad, Carsten Goessl, Noel W. Clarke, Vincenzo Emanuele Chiurì and Paweł Wiechno and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
In The Last Decade
Maria Learoyd
24 papers receiving 990 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Maria Learoyd United Kingdom | 15 | 559 | 367 | 295 | 163 | 159 | 25 | 1.0k | ||
| Chang Yang China | 13 | 250 0.4× | 498 1.4× | 115 0.4× | 31 0.2× | 32 0.2× | 37 | 953 | ||
| G L Scheffer Netherlands | 13 | 1.3k 2.3× | 780 2.1× | 132 0.4× | 20 0.1× | 40 0.3× | 14 | 1.7k | ||
| Elaine Paul United States | 13 | 950 1.7× | 363 1.0× | 130 0.4× | 26 0.2× | 48 0.3× | 22 | 1.1k | ||
| M. Piccart Belgium | 9 | 471 0.8× | 181 0.5× | 111 0.4× | 30 0.2× | 54 0.3× | 23 | 1.1k | ||
| Mauro Piccirillo Italy | 20 | 265 0.5× | 171 0.5× | 151 0.5× | 64 0.4× | 20 0.1× | 44 | 1.1k | ||
| Hongfeng Gou China | 13 | 447 0.8× | 335 0.9× | 130 0.4× | 15 0.1× | 36 0.2× | 60 | 968 | ||
| Junko Kikuchi Japan | 18 | 408 0.7× | 572 1.6× | 348 1.2× | 24 0.1× | 62 0.4× | 47 | 1.1k | ||
| P. A. Philip United States | 21 | 800 1.4× | 601 1.6× | 436 1.5× | 15 0.1× | 49 0.3× | 81 | 1.5k | ||
| Lada Krilov United States | 8 | 300 0.5× | 220 0.6× | 152 0.5× | 24 0.1× | 36 0.2× | 9 | 708 | ||
| Zhiping Ruan China | 21 | 408 0.7× | 721 2.0× | 212 0.7× | 20 0.1× | 28 0.2× | 58 | 1.2k |
Countries citing papers authored by Maria Learoyd
Since
Specialization
Citations
This map shows the geographic impact of Maria Learoyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Learoyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Learoyd more than expected).
Fields of papers citing papers by Maria Learoyd
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Maria Learoyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Learoyd. The network helps show where Maria Learoyd may publish in the future.
Co-authorship network of co-authors of Maria Learoyd
This figure shows the co-authorship network connecting the top 25 collaborators of Maria Learoyd. A scholar is included among the top collaborators of Maria Learoyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Learoyd. Maria Learoyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
González, Ignacio Ferreira, et al.. (2024). Population Pharmacokinetic Analysis of Selumetinib and Its N‐desmethyl Metabolite in Japanese and Non‐Japanese Pediatric Patients with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas. Journal of Clinical Pharmacy and Therapeutics. 2024(1).
2.
Viskochil, David, et al.. (2024). Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas. Neuro-Oncology Advances. 6(1). vdae036–vdae036.
3.
Rolfo, Christian, Judith de Vos‐Geelen, Nicolás Isambert, et al.. (2019). Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. Clinical Pharmacokinetics. 58(9). 1165–1174.
4.
Yuan, Peng, Jianzhong Shentu, Jianming Xu, et al.. (2019). Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 83(5). 963–974.
5.
Domchek, S. M., Sophie Postel‐Vinay, Y-J. Bang, et al.. (2018). Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC). Cancer Research. 78(4_Supplement). PD6–11.
6.
Clarke, Noel W., Paweł Wiechno, B. Yа. Alekseev, et al.. (2018). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology. 19(7). 975–986.
7.
Plummer, Ruth, Henk M.W. Verheul, Filip De Vos, et al.. (2018). Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Advances in Therapy. 35(11). 1945–1964.
8.
Zhou, Diansong, Jianguo Li, Khanh Bui, et al.. (2018). Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clinical Pharmacokinetics. 58(5). 615–625.
9.
Drew, Yvette, Maja J.A. de Jonge, Sook Hee Hong, et al.. (2018). An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecologic Oncology. 149. 246–247.
10.
Rolfo, Christian, Judith de Vos‐Geelen, Nicolás Isambert, et al.. (2017). PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT. Clinical Pharmacology & Therapeutics. 101.
11.
Nicolau, David P., Leonard Siew, J. Armstrong, et al.. (2015). Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy. 70(10). 2862–2869.
12.
Li, Jianguo, et al.. (2015). A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects. Clinical Drug Investigation. 36(2). 119–126.
13.
Edeki, Timi, et al.. (2015). Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. Journal of Infection and Chemotherapy. 21(8). 551–558.
14.
Sunzel, Maria, et al.. (2015). An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis. International Journal of Antimicrobial Agents. 46(6). 682–688.
15.
Das, Shampa, Jianguo Li, J. Armstrong, Maria Learoyd, & Timi Edeki. (2015). Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacology Research & Perspectives. 3(5). e00172–e00172.
16.
Tjulandin, S., Vladimir Moiseyenko, В. В. Семиглазов, et al.. (2013). Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Investigational New Drugs. 32(1). 145–153.
17.
Cohen, Roger B., Steinar Aamdal, Marta Nyakas, et al.. (2013). A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. European Journal of Cancer. 49(7). 1521–1529.
18.
Leijen, Suzanne, Patricia M.M.B. Soetekouw, T.R. Jeffry Evans, et al.. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(6). 1619–1628.
19.
O’Neil, Bert H., Laura W. Goff, John Kauh, et al.. (2011). Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology. 29(17). 2350–2356.
20.
López-Martín, José A., et al.. (2011). Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P).. Journal of Clinical Oncology. 29(15_suppl). 3105–3105.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chang Yang Breakdown of academic impact, for papers by G L Scheffer Breakdown of academic impact, for papers by Elaine Paul Breakdown of academic impact, for papers by M. Piccart Breakdown of academic impact, for papers by Mauro Piccirillo Breakdown of academic impact, for papers by Hongfeng Gou Breakdown of academic impact, for papers by Junko Kikuchi Breakdown of academic impact, for papers by P. A. Philip Breakdown of academic impact, for papers by Lada Krilov Breakdown of academic impact, for papers by Zhiping Ruan